Targeted Genetics Completes Dosing for Phase I/II Arthritis Trial

Targeted Genetics has announced that dosing has been completed for the Phase I/II clinical trial of tgAAC94 for the treatment of inflammatory arthritis.

The interim data from this ongoing Phase I/II clinical trial shows that tgAAC94 is well-tolerated at the highest dose tested in the trial and demonstrate that a higher percentage of subjects who received tgAAC94 showed improvement in function and pain compared to results from the placebo injected group.

Additional protocols are currently being developed to evaluate efficacy and duration of response, as well as to further assess safety, in patients with inflammatory arthritis who have one or few inflamed joints and are not candidates for systemic therapy or do not fully respond to systemic anti-TNF protein therapy.

Stewart Parker, president and CEO of Targeted Genetics, said: “Our targeted therapy candidate is designed to reduce inflammation locally in the joints and avoid the potential for systemic side effects. We believe tgAAC94 has the potential to improve the treatment of this serious disease.”